Portal de Periódicos da CAPES

Effects of tiotropium and other long acting bronchodilators in chronic obstructive pulmonary disease

2005; Elsevier BV; Volume: 19; Issue: 2 Linguagem: Inglês

10.1016/j.pupt.2005.04.003

1522-9629

Graeme P. Currie, Catherine Rossiter, Sean A. Miles, Daniel K.C. Lee, Owen Dempsey,

Respiratory and Cough-Related Research

Chronic obstructive pulmonary disease (COPD) accounts for a major workload in both primary and secondary care. It is characterised by progressive airflow obstruction which does not fully reverse to inhaled or oral pharmacotherapy. The diagnosis should be considered in any current or former smoker who has symptoms of breathlessness, wheeze, cough, sputum production and impaired exercise tolerance. From a pharmacological perspective, short-acting bronchodilators (anti-cholinergics and beta(2)-agonists) play a vital role in immediate relief of symptoms. However, in patients with persistent symptoms and exacerbations, long-acting bronchodilator therapy is advocated for regular use. Tiotropium is a newly introduced long-acting anti-cholinergic which facilitates once daily administration. This evidence based review article discusses the use of long acting bronchodilators in COPD with a particular emphasis on the putative benefits of tiotropium.